Italy
About Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A., along with its subsidiaries, is a global pharmaceutical company engaged in the research, development, production, and sale of pharmaceuticals. The company operates in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and other international markets.
Business Segments
- Specialty and Primary Care – Focuses on a broad range of therapeutic areas.
- Rare Diseases – Specializes in treatments for uncommon medical conditions.
Key Products and Developments
- Rare Disease Treatments: REC 0545 (maple syrup urine disease), Isturia (Cushing’s syndrome), Cystadrops (corneal cystine deposits), Carbaglu (hyperammonemia), Qarziba (neuroblastoma), and Fortivda (renal cell carcinoma).
- Oncology & Hematology: Sylvant (Castleman disease), ENJAYMO (cold agglutinin disease), Eligard (prostate cancer).
- Cardiovascular & Hypertension: Zanidip, Zanipress, Logimax, and Seloken.
- Urology & Men’s Health: Urorec and Avodart (benign prostatic hyperplasia).
- Infectious & Inflammatory Diseases: Polydexa, Isofra, Otofa (ENT infections), Tergynan (gynecological infections), Lomexin (dermatological infections).
- Gastrointestinal & Dietary: CitraFleet, Phosphosoda (bowel cleansers), Magnesio Supremo (dietary supplement).
- Other Treatments: Procto-Glyveno (hemorrhoids), Reaglia (schizophrenia), Hexaspray (throat spray).
Pipeline & Research
The company is actively developing new treatments, including:
- REC 0559 for neurotrophic keratitis.
- Pasireotide (Phase II trial for post-bariatric hypoglycemia).
Company Background
Founded in 1926, Recordati is headquartered in Milan, Italy, and has established itself as a key player in the global pharmaceutical industry.
